Alex A. Adjei, MD, PhD

Our physician editor-in-chief highlights the February 2015 issue of The Journal of Targeted Therapies in Cancer.

The RAS-RAF-MEK-extracellular signal–regulated kinase 1 and 2 (ERK1/2) pathway is the most mutated pathway in human cancer. Thus, components of this pathway have been seen as promising targets for cancer therapy.

Alex A. Adjei, MD, PhD, discusses the use of MEK inhibitors when treating patients with melanoma.